Pre-TKI cytokine profiling predicts CP–CML outcome
Measuring levels of transforming growth factor-α and interleukin-6 may help identify patients with newly diagnosed chronic phase–chronic myeloid leukaemia at risk of a poor outcome from tyrosine kinase inhibitor therapy, research suggests. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
KEYNOTE-001 findings add support to pembrolizumab for advanced melanoma
A third of patients with advanced or metastatic melanoma will achieve an objective response to treatment with the programmed cell death protein inhibitor pembrolizumab, suggest KEYNOTE-001 findings, regardless of whether they have previously been treated with ipilimumab. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Melanoma Source Type: news
Frontline nilotinib supported for newly diagnosed CP–CML
Long-term results from the ENESTnd trial indicate a favourable risk–benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase–chronic myeloid leukaemia diagnosis. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Imatinib-related symptom burden linked to adherence in Indian CML patients
Research shows low adherence to imatinib in Indian patients with chronic myeloid leukaemia, with an association between nonadherence and worse symptom burden related to treatment. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Spinal cord injury research goes from strength to strength
Technological advances allowing movement restoration in a man with quadriplegia, rodent studies showing successful regeneration of corticospinal projection, and improved understanding and treatment of systemic immune suppression in spinal cord injury have been reported in three Nature publications, offering possibilities for clinical translation and hope to patients with SCI. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Neurology Source Type: news
Diabetes drugs cleared of vascular harm
Two studies suggest that neither sulfonylureas nor sitagliptin increase the risk of adverse cardiovascular outcomes in patients with Type 2 diabetes. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Diabetes Source Type: news
Prognostic scores aid treatment conformity after ICH
Physicians’ prognosis and recommendations for patients after intracerebral haemorrhage vary considerably, report researchers who show the potential benefits of a validated prognostic score. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Neurology Source Type: news
Small fibre neuropathy defies ‘dying-back’ nerve process
Neuronal degradation in patients with small fibre neuropathy is not dependent on nerve fibre length, study findings suggest. (Source: MedWire News)
Source: MedWire News - April 19, 2016 Category: Consumer Health News Tags: Neurology Source Type: news
MR may detect earliest Alzheimer’s brain changes
medwireNews: Levels of the brain metabolite and neuroinflammation marker myo-inositol are elevated in asymptomatic patients with abnormal Alzheimer’s disease (AD) biomarkers, say researchers. As repo ... (Source: MedWire News)
Source: MedWire News - April 19, 2016 Category: Consumer Health News Tags: Alzheimer ' s disease Source Type: news
Promising osimertinib results presented at ELCC
Two studies presented at this year’s European Lung Cancer Conference in Geneva, Switzerland, focus on the third-generation tyrosine kinase inhibitor osimertinib in patients with advanced EGFR-mutated non-small-cell lung cancer. (Source: MedWire News)
Source: MedWire News - April 19, 2016 Category: Consumer Health News Tags: Non-small-cell lung cancer Source Type: news
EZH2 potential target in cutaneous basal cell carcinoma
The expression of the histone methyltransferase EZH2 correlates with aggressive subtypes of cutaneous basal cell carcinoma, highlighting the possibility that EZH2 may be an actionable target in this malignancy, say researchers. (Source: MedWire News)
Source: MedWire News - April 15, 2016 Category: Consumer Health News Tags: Oncology Source Type: news
Dose-sparing romidepsin regimen promising in cutaneous T-cell lymphoma
Patients with cutaneous T-cell lymphoma who respond to the standard romidepsin dosing regimen could benefit from transitioning to a dose-sparing schedule, suggests a case series published in JAMA Oncology. (Source: MedWire News)
Source: MedWire News - April 15, 2016 Category: Consumer Health News Tags: Lymphoma Source Type: news
Alzheimer’s preclinical staging criteria supported
The Alzheimer’s disease preclinical staging criteria proposed by the National Institute on Aging and the Alzheimer’s Association appear to be valid over more than a decade of follow-up, say researchers. (Source: MedWire News)
Source: MedWire News - April 15, 2016 Category: Consumer Health News Tags: Alzheimer ' s disease Source Type: news
AAN 68th annual meeting
Research from the American Academy of Neurology’s 68th Annual Meeting in Vancouver, British Columbia, Canada, shows that a common antihistamine could partially reverse chronic vision damage in patients with multiple sclerosis and a once-a-day epilepsy treatment may be comparable to one taken twice a day for controlling seizures. (Source: MedWire News)
Source: MedWire News - April 15, 2016 Category: Consumer Health News Tags: Neurology Source Type: news
Physicians failing to talk to stroke patients about end-of-life treatment preferences
US research suggests that physician–patient discussion about limitations on life-sustaining interventions following ischaemic stroke is low, poorly documented and often left too late. (Source: MedWire News)
Source: MedWire News - April 13, 2016 Category: Consumer Health News Tags: Stroke Source Type: news
